122 related articles for article (PubMed ID: 20197380)
1. MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo.
Huck JJ; Zhang M; McDonald A; Bowman D; Hoar KM; Stringer B; Ecsedy J; Manfredi MG; Hyer ML
Mol Cancer Res; 2010 Mar; 8(3):373-84. PubMed ID: 20197380
[TBL] [Abstract][Full Text] [Related]
2. Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence.
Liu Y; Hawkins OE; Su Y; Vilgelm AE; Sobolik T; Thu YM; Kantrow S; Splittgerber RC; Short S; Amiri KI; Ecsedy JA; Sosman JA; Kelley MC; Richmond A
EMBO Mol Med; 2013 Jan; 5(1):149-66. PubMed ID: 23180582
[TBL] [Abstract][Full Text] [Related]
3. Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma.
Brockmann M; Poon E; Berry T; Carstensen A; Deubzer HE; Rycak L; Jamin Y; Thway K; Robinson SP; Roels F; Witt O; Fischer M; Chesler L; Eilers M
Cancer Cell; 2013 Jul; 24(1):75-89. PubMed ID: 23792191
[TBL] [Abstract][Full Text] [Related]
4. Aurora A Kinase Plays a Key Role in Mitosis Skip during Senescence Induced by Ionizing Radiation.
Zhang XR; Zhang TS; Zhang YN; Hua JR; Wang JF; He JP
Biomed Environ Sci; 2023 Oct; 36(10):903-916. PubMed ID: 37932059
[TBL] [Abstract][Full Text] [Related]
5. Therapy-induced senescence as a component of tumor biology: Evidence from clinical cancer.
Saleh T; Bloukh S; Hasan M; Al Shboul S
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):188994. PubMed ID: 37806641
[TBL] [Abstract][Full Text] [Related]
6. Correction: Elsherbeny et al. 2-(3-Bromophenyl)-8-fluoroquinazoline-4-carboxylic Acid as a Novel and Selective Aurora A Kinase Inhibitory Lead with Apoptosis Properties: Design, Synthesis, In Vitro and In Silico Biological Evaluation.
Elsherbeny MH; Ammar UM; Abdellattif MH; Abourehab MAS; Abdeen A; Ibrahim SF; Abdelrahaman D; Mady W; Roh EJ; Elkamhawy A
Life (Basel); 2024 Mar; 14(4):. PubMed ID: 38672808
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.
Manfredi MG; Ecsedy JA; Chakravarty A; Silverman L; Zhang M; Hoar KM; Stroud SG; Chen W; Shinde V; Huck JJ; Wysong DR; Janowick DA; Hyer ML; Leroy PJ; Gershman RE; Silva MD; Germanos MS; Bolen JB; Claiborne CF; Sells TB
Clin Cancer Res; 2011 Dec; 17(24):7614-24. PubMed ID: 22016509
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
Payton M; Bush TL; Chung G; Ziegler B; Eden P; McElroy P; Ross S; Cee VJ; Deak HL; Hodous BL; Nguyen HN; Olivieri PR; Romero K; Schenkel LB; Bak A; Stanton M; Dussault I; Patel VF; Geuns-Meyer S; Radinsky R; Kendall RL
Cancer Res; 2010 Dec; 70(23):9846-54. PubMed ID: 20935223
[TBL] [Abstract][Full Text] [Related]
9. MLN8054, a small molecule inhibitor of aurora kinase a, sensitizes androgen-resistant prostate cancer to radiation.
Moretti L; Niermann K; Schleicher S; Giacalone NJ; Varki V; Kim KW; Kopsombut P; Jung DK; Lu B
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1189-97. PubMed ID: 21514073
[TBL] [Abstract][Full Text] [Related]
10. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
11. Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma.
Van Brocklyn JR; Wojton J; Meisen WH; Kellough DA; Ecsedy JA; Kaur B; Lehman NL
Cancer Res; 2014 Oct; 74(19):5364-70. PubMed ID: 25106428
[TBL] [Abstract][Full Text] [Related]
12. Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies.
Chinn DC; Holland WS; Mack PC
J Cancer Res Clin Oncol; 2014 Jul; 140(7):1137-49. PubMed ID: 24756365
[TBL] [Abstract][Full Text] [Related]
13. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.
Palani S; Patel M; Huck J; Zhang M; Balani SK; Yang J; Chen S; Mettetal J; Manfredi M; Shyu WC; Ecsedy JA; Chakravarty A
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1255-64. PubMed ID: 24101146
[TBL] [Abstract][Full Text] [Related]
14. p53 deficiency enhances mitotic arrest and slippage induced by pharmacological inhibition of Aurora kinases.
Marxer M; Ma HT; Man WY; Poon RY
Oncogene; 2014 Jul; 33(27):3550-60. PubMed ID: 23955083
[TBL] [Abstract][Full Text] [Related]
15. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.
Sehdev V; Peng D; Soutto M; Washington MK; Revetta F; Ecsedy J; Zaika A; Rau TT; Schneider-Stock R; Belkhiri A; El-Rifai W
Mol Cancer Ther; 2012 Mar; 11(3):763-74. PubMed ID: 22302096
[TBL] [Abstract][Full Text] [Related]
16. Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237.
Sloane DA; Trikic MZ; Chu ML; Lamers MB; Mason CS; Mueller I; Savory WJ; Williams DH; Eyers PA
ACS Chem Biol; 2010 Jun; 5(6):563-76. PubMed ID: 20426425
[TBL] [Abstract][Full Text] [Related]
17. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.
Görgün G; Calabrese E; Hideshima T; Ecsedy J; Perrone G; Mani M; Ikeda H; Bianchi G; Hu Y; Cirstea D; Santo L; Tai YT; Nahar S; Zheng M; Bandi M; Carrasco RD; Raje N; Munshi N; Richardson P; Anderson KC
Blood; 2010 Jun; 115(25):5202-13. PubMed ID: 20382844
[TBL] [Abstract][Full Text] [Related]
18. Detection of senescence using machine learning algorithms based on nuclear features.
Duran I; Pombo J; Sun B; Gallage S; Kudo H; McHugh D; Bousset L; Barragan Avila JE; Forlano R; Manousou P; Heikenwalder M; Withers DJ; Vernia S; Goldin RD; Gil J
Nat Commun; 2024 Feb; 15(1):1041. PubMed ID: 38310113
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and evaluation of a novel PET imaging agent targeting lipofuscin in senescent cells.
Brickute D; Chen C; Braga M; Barnes C; Wang N; Allott L; Aboagye EO
RSC Adv; 2022 Sep; 12(40):26372-26381. PubMed ID: 36275107
[TBL] [Abstract][Full Text] [Related]
20. Targeting senescence as an anticancer therapy.
Bousset L; Gil J
Mol Oncol; 2022 Nov; 16(21):3855-3880. PubMed ID: 36065138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
